FDA approves drug that helps slow progression of rare form of motor neuron disease

by

The Food and Drug Administration (FDA) in the U.S. has authorized the first approved drug for a rare form of motor neuron disease (MND) based on the results of a Phase 3 clinical trial completed at the University of Sheffield, the U.K. center for the international trial.

Leave A Comment

Your email address will not be published. Required fields are marked *